Education
About Us
Working with TipRanks
Follow Us
Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2)
SGX:9G2
9G2 Stock Chart & Stats
S$0.07
S$0.00(0.00%)
At close: 4:00 PM EST
S$0.07
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume159.90K
Average Volume (3M)247.96K
Market Cap
S$59.11M
Enterprise ValueS$134.93M
Total Cash (Recent Filing)S$3.85M
Total Debt (Recent Filing)S$88.57M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,231,494,600
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Strong Revenue Growth (95.43%)Sustained ~95% top-line expansion provides a larger revenue base and evidences demand or successful commercial traction. Over months this scale can help absorb fixed costs, support reinvestment in services or capacity, and enable path to operating leverage if margins improve.
High Free Cash Flow Growth (91.31%)A near-doubling in free cash flow growth suggests improving cash conversion trends even if levels are currently negative. If sustained, this dynamic reduces future external funding needs, supports working capital and capex funding, and indicates operational improvements over the medium term.
Relatively Stable Equity RatioA stable equity base provides a solvency buffer against shocks and helps retain creditor confidence. That stability supports access to capital and preserves operational continuity while management works to convert revenue growth into durable profitability and cash generation.
Bears Say
Persistent Negative ProfitabilityConsistent negative EBIT and net margins show the business is not converting revenue into profit. Continued losses erode retained earnings, restrict reinvestment, and prolong dependence on external funding. Without margin improvement, growth may not translate into shareholder value.
Negative Operating Cash FlowCore operations consuming cash indicates the business is not self-funding day-to-day activities. Persistent negative operating cash flow raises liquidity risk, increases reliance on debt or equity raises, and may force trade-offs on capex or growth initiatives if not reversed.
Elevated Leverage (debt-to-equity 1.05)A debt/equity ratio above 1 signals significant leverage that amplifies financial risk, especially given operating losses and negative cash flow. High leverage constrains strategic flexibility, raises refinancing and interest burden, and increases downside vulnerability over the medium term.
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$59.11M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Nov 03, 2026 which is in 233 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on Feb 13, 2026. The company reported -S$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.009.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,231,494,600 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.69%
12-Months-Change
Fundamentals
Return on Equity
-47.62%
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.